Denali Therapeutics Quarterly Cash Flow Statement
NASDAQ: DNLIHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Denali Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Denali Therapeutics generated -$97.0 million of operating cash flow and spent $805,000 on capital expenditures. That left free cash flow of -$97.8 million, a free-cash-flow margin of -2713.8% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Denali Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -127.55M | -128.45M | -128.55M | -126.90M | -124.12M | -132.97M | -114.75M | -107.19M | -99.03M | -101.80M | -119.47M | -99.35M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | -154.00% | — | — | — |
| Depreciation & Amortization | 3.57M | 2.85M | 2.87M | 2.95M | 3.04M | 2.33M | 1.85M | 1.84M | 1.94M | 2.16M | 2.18M | 2.22M |
| Stock-Based Compensation | 22.91M | 23.09M | 23.95M | 25.14M | 25.39M | 25.16M | 25.08M | 24.86M | 25.10M | 27.84M | 25.99M | 27.46M |
| Change in Working Capital | -95.00K | 1.58M | -1.66M | -2.71M | 27.55M | -31.25M | 1.43M | 13.34M | 2.32M | -18.13M | -8.09M | -3.87M |
| Operating Cash Flow | -97.00M | -131.20M | -98.54M | -107.30M | -75.30M | -131.47M | -83.72M | -59.14M | -91.22M | -113.62M | -98.66M | -87.36M |
| Capital Expenditures | -805.00K | -2.47M | -1.52M | 1.38M | -4.28M | -5.08M | -5.09M | -3.88M | -4.79M | -2.15M | -2.23M | -2.07M |
| Investing Cash Flow | -104.08M | 94.46M | 20.77M | 57.83M | 157.94M | 18.75M | 172.21M | 93.66M | 98.57M | -453.19M | 73.05M | 100.91M |
| Financing Cash Flow | 14.98M | 219.04M | 192.13M | -778.00K | 1.62M | -3.76M | -4.17M | -18.56M | 6.76M | 500.27M | 4.71M | 2.49M |
| Net Change in Cash | -186.10M | 182.30M | 114.36M | -50.24M | 84.26M | -116.48M | 84.32M | 15.96M | 14.11M | -66.53M | -20.91M | 16.04M |
| Free Cash Flow | -97.81M | -133.67M | -100.06M | -105.92M | -79.58M | -136.55M | -88.81M | -63.02M | -96.01M | -115.77M | -100.89M | -89.43M |
This table shows 12 quarterly periods of Denali Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow DNLI's reporting calendar. What is a cash flow statement?